Risk of tuberculosis with anti-tumor necrosis factor-α therapy: Substantially higher number of patients at risk in Asia

International Journal of Rheumatic Diseases

Volumn 17, Issue 3, 2014, Pages 291-298

  Navarra, Sandra V ^a   Tang, Boxiong ^b   Lu, Liangjing ^c   Lin, Hsiao Yi ^d   Mok, Chi Chiu ^e   Asavatanabodee, Paijit ^f   Suwannalai, Parawee ^g   Hussein, Heselynn ^h   Rahman, Mahboob U ^b,i  

^a UNIVERSITY OF SANTO TOMAS   (Philippines)

^b PFIZER INC   (United States)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e TUEN MUN HOSPITAL   (Hong Kong)

^f PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^g MAHIDOL UNIVERSITY   (Thailand)

^h PUTRAJAYA HOSPITAL   (Malaysia)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Ankylosing spondylitis; Health services and health care economics; Psoriatic arthritis; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANKYLOSING SPONDYLITIS; ARTICLE; ASIA; COMPARATIVE STUDY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; NORTH AMERICA; NUMBERS NEEDED TO TREAT; POPULATION; POPULATION RESEARCH; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; STANDARDIZED INCIDENCE RATIO; TUBERCULOSIS; WESTERN EUROPE; ANTAGONISTS AND INHIBITORS; EPIDEMIOLOGY; EUROPE; FEMALE; INCIDENCE; MALE; REGISTER; RHEUMATIC DISEASES; RISK FACTOR;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ASIA; EUROPE; FEMALE; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; MALE; NORTH AMERICA; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; RHEUMATIC DISEASES; RISK FACTORS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84897024635     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12188     Document Type: Article

References (39)

1. Wiedmann MW, Mössner J, Baerwald C, Pierer M (2009) TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases. Endocr Metab Immune Disord Drug Targets 9, 295-314.
2. Silva LC, Ortigosa LC, Benard G (2010) Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2, 817-33.
3. Askling J, Fored CM, Brandt L et al. (2005) Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52, 1986-92.
4. Dixon WG, Watson K, Lunt M et al. (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54, 2368-76.
5. Ellerin T, Rubin RH, Weinblatt ME (2003) Infections and anti-tumor necrosis factor-α therapy. Arthritis Rheum 48, 3013-22.
6. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48, 2122-7.
7. Keane J, Gershon S, Wise RP et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor-neutralizing agent. N Engl J Med 345, 1098-104.
8. Seong SS, Choi CB, Woo JH et al. (2007) Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 34, 706-11.
9. Wolfe F, Michaud K, Anderson J, Urbansky K (2004) Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 50, 372-9.
10. Mohan AK, Coté TR, Block JA, Manadan AM, Siegel JN, Braun MM (2004) Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 39, 295-9.
11. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38, 1261-5.
12. Wallis RS, Broder M, Wong J, Beenhouwer D (2004) Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 39, 1254-5.
13. Incidence of tuberculosis (per 100, 000 people). The World Bank Group Web site. [Accessed 23 March 2012.] Available from URL: http://data.worldbank.org/indicator/SH.TBS.INCD.
14. Tuberculosis factsheet (No. 104). World Health Organization Web site. [Accessed 23 March 2012.] Available from URL: http://www.who.int/mediacentre/factsheets/fs104/en/.
15. Tubach F, Salmon D, Ravaud P et al. (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60, 1884-94.
16. Taiwan Tuberculosis Control Report 2009. Center for Disease Control Taiwan Web site. [Accessed 30 April 2012.] Available from URL: http://www.cdc.gov.tw/uploads/files/cd38b0db-50f5–40ff-abfe-fd11902c1f0b.pdf.
17. Westhovens R, Yocum D, Han J et al. (2006) The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 54, 1075-86.
18. Schiff MH, Burmester GR, Kent JD et al. (2006) Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65, 889-94.
19. Hsia EC, Cush JJ, Matteson EL et al. (2013) Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in phase III clinical trials. Arthritis Care Res 65, 309-13.
20. Dabbous O, Gilmer K, Tatsuki Y et al. (2007) Tuberculosis in Japanese patients with rheumatoid arthritis treated with infliximab: findings from the post marketing surveillance trial. Ann Rheum Dis 66 (Suppl 2), 167.
21. Kim E, Uhm W, Bae S, Yoo DH, Kim TH (2011) Incidence of tuberculosis among Korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers. J Rheumatol 38, 2218-23.
22. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL (2008) Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 59, 800-6.
23. Navarra SV, Raso A, Lichauco JJ, Tan PP (2006) Clinical experience with infliximab among Filipino patients with rheumatic diseases. APLAR J Rheumatol 9, 150-6.
24. Dixon WG, Hyrich KL, Watson KD et al. (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69, 522-8.
25. Osiri M, Suarez-Almazor M, Wells G, Robinson V, Tugwell P (2003) Number needed to treat (NNT): implication in rheumatology clinical practice. Ann Rheum Dis 62, 316-21.
26. Citrome L (2007) Show me the evidence: using number needed to treat. South Med J 100, 881-4.
27. Straus SE (2002) Individualizing treatment decisions. The likelihood of being helped or harmed. Eval Health Prof 25, 210-24.
28. Kohno T, Tam LT, Stevens S, Louie JS (2007) Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs. J Investig Dermatol Symp Proc 12, 5-8.
29. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J (1995) Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 7, 251-9.
30. Scallon B, Cai A, Solowski N et al. (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301, 418-26.
31. Santora LC, Kaymakcalan Z, Sakorafas P, Krull IS, Grant K (2001) Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem 299, 119-29.
32. Siegel SA, Shealy DJ, Nakada MT et al. (1995) The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 7, 15-25.
33. Oka H, Nishioka K, Togo M, Ochi T (2006) The efficacy of infliximab for patients with rheumatoid arthritis in Japan: results of 5000 cases by post-marketing surveillance data. APLAR J Rheumatol 9, 142-5.
34. Zhang FC, Hou Y, Huang F et al. (2006) Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China. APLAR J Rheumatol 9, 127-30.
35. Kumar A (2006) Experience with anti-tumor necrosis factor-α therapy in India. APLAR J Rheumatol 9, 136-41.
36. Malaviya AN, Kapoor S, Garg S et al. (2009) Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India - An audit report. J Rheumatol 36, 1414-20.
37. Lichauco JJ, Tankeh-Torres SA, Navarra SV, Dans LF, for the Task Force for TB Screening Prior to Use of Biologic Agents (2006) Philippine guidelines on the screening for tuberculosis prior to the use of biologic agents. APLAR J Rheumatol 9, 184-92.
38. Mok CC, Tam LS, Chan TH et al. (2011) Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. Clin Rheumatol 30, 303-12.
39. Singh JA, Furst DE, Bharat A et al. (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 64, 625-39.